Matched-sibling allogeneic bone marrow transplants in young patients with aplastic anemia have an excellent outcome, with survival rates approaching 90% with current supportive care.2–4 The quality of life for these patients is outstanding as well. Aplastic anemia is the only indication for urgent bone marrow transplantation when a fully matched relative is identified. GVHD is a significant concern and influences outcomes after transplantation. For this reason, the focus of current research is reducing the incidence of GVHD in patients undergoing bone marrow transplantation.
2. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 2005;130:747–51.
3. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995;85:3058–65.
4. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004;103:2490–7.
Click here to return to the questions
Seminars in Medical Practice
Hospital Physician Board Review Manuals
Copyright © 2009, Turner White Communications
Updated 2/05/2009 nvf